Network pharmacology analysis clarified a potential mechanism underlying the role of SJZD in the CRC TME and indicated that HSPB1, SPP1, IGFBP2 and TGFB1 could be potential therapeutic targets in the CRC TME. This evidence concerns the gene HSPB1 and colorectal carcinoma.